Antibodies, Monoclonal, Humanized

• 

  Subject Areas on Research

  • 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). 
  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 
  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. 
  • A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. 
  • A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. 
  • A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. 
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. 
  • A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. 
  • A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. 
  • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. 
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 
  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. 
  • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. 
  • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. 
  • A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. 
  • A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy. 
  • A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 
  • A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. 
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). 
  • A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. 
  • Acute myelogenous leukemia associated with Ollier disease. 
  • Adalimumab for the treatment of psoriasis. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow. 
  • Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. 
  • Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. 
  • Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. 
  • Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. 
  • Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. 
  • Alemtuzumab induction in lung transplantation: time to move on? 
  • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. 
  • Alemtuzumab. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. 
  • An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. 
  • Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. 
  • Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. 
  • Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 
  • Anti-angiogenic therapy in renal cell cancer. 
  • Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. 
  • Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. 
  • Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. 
  • Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. 
  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). 
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. 
  • Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. 
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. 
  • Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. 
  • Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. 
  • Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. 
  • Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. 
  • Author reply: To PMID 24393349. 
  • Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. 
  • Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications. 
  • Avastin: more questions than answers. . . 
  • BAFF is increased in renal transplant patients following treatment with alemtuzumab. 
  • BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). 
  • Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. 
  • Best practices for treatment of retinal vein occlusion. 
  • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). 
  • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 
  • Bevacizumab and daily temozolomide for recurrent glioblastoma. 
  • Bevacizumab and everolimus in renal cancer: a rational way forward. 
  • Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. 
  • Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. 
  • Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. 
  • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 
  • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. 
  • Bevacizumab therapy for glioblastoma: a passionate discussion. 
  • Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. 
  • Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. 
  • Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. 
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. 
  • Bronchiolitis. 
  • CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. 
  • CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. 
  • CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. 
  • Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. 
  • Campath-1H in intestinal and multivisceral transplantation: preliminary data. 
  • Campath-1H in renal transplantation: The University of Wisconsin experience. 
  • Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. 
  • Campath-1H use in pediatric renal transplantation. 
  • Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. 
  • Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". 
  • Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. 
  • Cell signaling modifiers in prostate cancer. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Certolizumab pegol. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. 
  • Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. 
  • Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. 
  • Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. 
  • Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. 
  • Clinical update: new treatments for age-related macular degeneration. 
  • Colon cancer, version 3.2014. 
  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 
  • Combined modality treatment for rectal cancer. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas. 
  • Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. 
  • Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. 
  • Corneal penetration of topical and subconjunctival bevacizumab. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. 
  • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. 
  • Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. 
  • Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. 
  • D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 
  • Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. 
  • Diagnosing acute myocardial infarction in patients with left bundle branch block. 
  • Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. 
  • Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. 
  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Discontinuation and management of direct-acting anticoagulants for emergency procedures. 
  • Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. 
  • Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. 
  • Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. 
  • Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. 
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. 
  • Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. 
  • Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. 
  • Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. 
  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. 
  • Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. 
  • Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. 
  • Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. 
  • Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. 
  • Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. 
  • Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. 
  • Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. 
  • Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. 
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 
  • Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. 
  • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 
  • Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. 
  • Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. 
  • Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. 
  • Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? 
  • Emerging treatments for ulcerative colitis: a systematic review. 
  • Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons. 
  • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
  • Epidermal growth factor receptor-targeted therapy for pancreatic cancer. 
  • Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. 
  • Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. 
  • Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. 
  • Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus. 
  • Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. 
  • FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. 
  • Finding the right job for the tool: alemtuzumab and its role in renal transplantation. 
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. 
  • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 
  • Glioblastoma stem-like cells give rise to tumour endothelium. 
  • HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. 
  • Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. 
  • Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors. 
  • Hidden biases in an observational study of bevacizumab beyond progression. 
  • How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? 
  • Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. 
  • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 
  • Idarucizumab for Dabigatran Reversal. 
  • Idarucizumab for dabigatran overdose. 
  • Idarucizumab since FDA approval: Use in the real-world. 
  • Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. 
  • Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. 
  • Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. 
  • Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. 
  • Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. 
  • In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. 
  • Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. 
  • Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. 
  • Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. 
  • Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. 
  • Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. 
  • Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. 
  • Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. 
  • Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. 
  • Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. 
  • Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. 
  • Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. 
  • Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. 
  • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
  • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. 
  • Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. 
  • Life threatening liver disease during treatment with monoclonal antibodies. 
  • Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. 
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. 
  • Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. 
  • Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. 
  • Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. 
  • Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. 
  • Making genuine progress against metastatic breast cancer. 
  • Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. 
  • Management of hearing in pediatric NF2. 
  • Marked clinical and jitter improvement after eculizumab in refractory myasthenia. 
  • Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. 
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Molecular markers for incidence, prognosis, and response to therapy. 
  • Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? 
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 
  • Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma? 
  • Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. 
  • New and emerging therapies for bone metastases in genitourinary cancers. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. 
  • Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. 
  • Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. 
  • Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. 
  • Novel oral anticoagulants and reversal agents: Considerations for clinical development. 
  • Novel--and "neu"--therapeutic possibilities for heart failure. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. 
  • Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. 
  • Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. 
  • Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. 
  • Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). 
  • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. 
  • PET concerns in bevacizumab treatment. 
  • PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. 
  • PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. 
  • Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. 
  • Pediatric neuro-Behçet's disease responsive to adalimumab. 
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. 
  • Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Pertuzumab protects the achilles' heel of trastuzumab--emtansine. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. 
  • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. 
  • Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. 
  • Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. 
  • Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. 
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. 
  • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. 
  • Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. 
  • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. 
  • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. 
  • Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. 
  • Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. 
  • Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. 
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer. 
  • Profile of adalimumab and its potential in the treatment of uveitis. 
  • Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). 
  • Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. 
  • Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. 
  • Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. 
  • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). 
  • Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. 
  • Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. 
  • Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis. 
  • Quality of life in ICON7: need for patients' perspectives. 
  • RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. 
  • Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. 
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. 
  • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
  • Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Ranibizumab and bevacizumab for neovascular age-related macular degeneration. 
  • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. 
  • Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. 
  • Ranibizumab for neovascular age-related macular degeneration. 
  • Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. 
  • Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. 
  • Reading speed improvements in retinal vein occlusion after ranibizumab treatment. 
  • Recurrent malignant gliomas. 
  • Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. 
  • Refractory myasthenia gravis exacerbation triggered By pembrolizumab. 
  • Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. 
  • Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? 
  • Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. 
  • Reperfusion edema after lung transplantation: effect of daclizumab. 
  • Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. 
  • Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). 
  • Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. 
  • Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD. 
  • Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration. 
  • Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. 
  • Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. 
  • Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. 
  • Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. 
  • Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. 
  • Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. 
  • Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. 
  • Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. 
  • Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. 
  • Spondyloarthritis in a patient with unilateral buttock pain and history of Crohn disease. 
  • Stem cell transplantation for multiple myeloma. 
  • Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes. 
  • Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. 
  • Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. 
  • Survival after brain metastases from breast cancer in the trastuzumab era. 
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. 
  • Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. 
  • Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. 
  • T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • Targeted therapies for cancer 2004. 
  • Targeted therapy in rectal cancer. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. 
  • Targeting the Effect of VEGF in Diabetic Macular Edema. 
  • Targeting the future in head and neck cancer. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 
  • The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals. 
  • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. 
  • The calm after the cytokine storm: lessons from the TGN1412 trial. 
  • The cam-path forward. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. 
  • The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma. 
  • The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. 
  • The impact of sharing results of a randomized breast cancer clinical trial with study participants. 
  • The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. 
  • The paradoxical effect of bevacizumab in the therapy of malignant gliomas. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. 
  • Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. 
  • Therapy of inflammatory bowel disease: what to expect in the next decade. 
  • Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. 
  • Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. 
  • Topical bevacizumab therapy for corneal neovascularization. 
  • Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. 
  • Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. 
  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 
  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. 
  • Trastuzumab emtansine for HER2-positive advanced breast cancer. 
  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. 
  • Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? 
  • Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. 
  • Treatment of age-related macular degeneration. 
  • Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. 
  • Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Treatment options in renal cell carcinoma: past, present and future. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. 
  • Trends in age-related macular degeneration management in Singapore. 
  • Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. 
  • Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. 
  • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. 
  • Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. 
  • Use of trastuzumab in the treatment of metastatic endometrial cancer. 
  • Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. 
  • VEGF inhibition and renal thrombotic microangiopathy. 
  • Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. 
  • Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. 
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 
  • Ziv-aflibercept: binding to more than VEGF-A--does more matter? 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Craciunescu, Oana, Associate Professor of Radiation Oncology, Radiation Oncology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Professor of Otolaryngology, Surgery, Head and Neck Surgery and Communication Sciences
  • Fekrat, Sharon, Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Medicine, Medical Oncology